^
Association details:
| Biomarker: | AR mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | bavdegalutamide (ARV-110) (Androgen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations
Published date:
10/16/2023
Excerpt:
Bavdeg had encouraging efficacy in post-NHA pts with mCRPC and AR 878/875 or any AR missense LBD mutation (excluding AR L702H alone) and was tolerable…
Trial ID:
